ABSTRACT
[Figure: see text].
Subject(s)
Atherosclerosis/etiology , Cell Dedifferentiation , MicroRNAs/metabolism , Muscle, Smooth, Vascular/physiology , RNA, Long Noncoding/physiology , Animals , Atherosclerosis/pathology , Cell Movement , Cell Proliferation , Clustered Regularly Interspaced Short Palindromic Repeats , Coronary Vessels/cytology , Down-Regulation , Gene Knockdown Techniques , Gene Silencing , Humans , Lipid Metabolism , Mice , Muscle, Smooth, Vascular/cytology , Oligonucleotides, Antisense , Phenotype , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , TranscriptomeABSTRACT
Noncoding RNAs (long noncoding RNAs and small RNAs) are emerging as critical modulators of phenotypic changes associated with physiological and pathological contexts in a variety of cardiovascular diseases (CVDs). Although it has been well established that hereditable genetic alterations and exposure to risk factors are crucial in the development of CVDs, other critical regulators of cell function impact on disease processes. Here we discuss noncoding RNAs have only recently been identified as key players involved in the progression of disease. In particular, we discuss micro RNA (miR)-143/145 since they represent one of the most characterised microRNA clusters regulating smooth muscle cell (SMC) differentiation and phenotypic switch in response to vascular injury and remodelling. MiR143HG is a well conserved long noncoding RNA (lncRNA), which is the host gene for miR-143/145 and recently implicated in cardiac specification during heart development. Although the lncRNA-miRNA interactions have not been completely characterised, their crosstalk is now beginning to emerge and likely requires further research focus. In this review we give an overview of the biology of the genomic axis that is miR-143/145 and MiR143HG, focusing on their important functional role(s) in the cardiovascular system.
